Marina Bagnoli
Overview
Explore the profile of Marina Bagnoli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
915
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ricci A, Dugo M, Pisanu M, De Cecco L, Raspagliesi F, Valeri B, et al.
J Proteome Res
. 2023 Dec;
23(1):483-493.
PMID: 38109371
Proton magnetic resonance spectroscopy (H-MRS) of surgically collected tumor specimens may contribute to investigating cancer metabolism and the significance of the "total choline" (Cho) peak (3.2 ppm) as malignancy and...
2.
Forlani L, De Cecco L, Simeon V, Paolini B, Bagnoli M, Cecere S, et al.
J Exp Clin Cancer Res
. 2023 Apr;
42(1):83.
PMID: 37041632
Background: Validated prognostic biomarkers for anti-angiogenic therapy using the anti-VEGF antibody Bevacizumab in ovarian cancer (OC) patients are still an unmet clinical need. The EGFR can contribute to cancer-associated biological...
3.
The deubiquitinase USP8 regulates ovarian cancer cell response to cisplatin by suppressing apoptosis
Corno C, Darcy P, Bagnoli M, Paolini B, Costantino M, Carenini N, et al.
Front Cell Dev Biol
. 2022 Dec;
10:1055067.
PMID: 36578788
The identification of therapeutic approaches to improve response to platinum-based therapies is an urgent need for ovarian carcinoma. Deubiquitinases are a large family of ubiquitin proteases implicated in a variety...
4.
Fabbi M, Costa D, Russo D, Arenare L, Gaggero G, Signoriello S, et al.
Diagnostics (Basel)
. 2022 Sep;
12(9).
PMID: 36140519
To find prognostic factors for advanced ovarian cancer patients undergoing first-line therapy with carboplatin, paclitaxel and bevacizumab, we investigated the expression of a disintegrin and metalloprotease 17 (ADAM17) in cancer...
5.
Distefano R, Tomasello L, Rampioni Vinciguerra G, Gasparini P, Xiang Y, Bagnoli M, et al.
Cancer Res
. 2022 Aug;
82(20):3687-3700.
PMID: 36040379
Significance: Modified miRNAs may act as cancer biomarkers and function as allies or antagonists of their canonical counterparts in gene regulation, suggesting the concurrent consideration of canonical and modified miRNAs...
6.
Bagnoli M, Nicoletti R, Valitutti M, Rizzo A, Napoli A, Montalvao De Azevedo R, et al.
Front Oncol
. 2022 Aug;
12:923508.
PMID: 35924161
Epithelial ovarian cancer (EOC) remains the most lethal gynecological cancer and development of chemo-resistance is a major factor in disease relapse. Homologous recombination (HR) is a critical pathway for DNA...
7.
Ditto A, De Cecco L, Paolini B, Alberti P, Martinelli F, Leone Roberti Maggiore U, et al.
Eur J Cancer
. 2021 Dec;
161:55-63.
PMID: 34922264
Aim: Early-stage epithelial ovarian cancer (eEOC) patients have a generally favorable prognosis but unpredictable recurrence. Accurate prediction of risk of relapse is still a major concern, essentially to avoid overtreatment....
8.
Marceca G, Distefano R, Tomasello L, Lagana A, Russo F, Calore F, et al.
Sci Data
. 2021 Aug;
8(1):199.
PMID: 34349127
MicroRNAs (miRNAs) are regulatory small non-coding RNAs that function as translational repressors. MiRNAs are involved in most cellular processes, and their expression and function are presided by several factors. Amongst,...
9.
De Cecco L, Bagnoli M, Chiodini P, Pignata S, Mezzanzanica D
Cancers (Basel)
. 2021 Apr;
13(7).
PMID: 33801595
Epithelial ovarian cancer (EOC) remains the second most common cause of gynecological cancer deaths. To improve patients' outcomes, we still need reliable biomarkers of early relapse, of which external independent...
10.
Rizzo A, Satta A, Garrone G, Cavalleri A, Napoli A, Raspagliesi F, et al.
J Exp Clin Cancer Res
. 2021 Jan;
40(1):5.
PMID: 33390181
Background: Choline kinase-α (ChoKα/CHKA) overexpression and hyper-activation sustain altered choline metabolism conferring the cholinic phenotype to epithelial ovarian cancer (OC), the most lethal gynecological tumor. We previously proved that CHKA...